International Oncology Network - Cancer & Hematology News

All Blog Posts Tagged 'gemcitabine' (5)

Study Confirms Improved Survival in Advanced Pancreatic Cancer with Nanoparticle Albumin-bound Paclitaxel plus Gemcitabine

A new phase III study confirms that the breast cancer drug nanoparticle albumin-bound paclitaxel (Abraxane®, Celgene) in combination with gemcitabine (Gemzar®, Eli Lilly and Company), the current standard of for advanced pancreatic cancer, demonstrated highly statistically significant and clinically meaningful results across primary and key secondary endpoints and patient…

Continue

Added by Peter Hofland, PhD on January 22, 2013 at 4:30pm — No Comments

Pre-Clinical Studies of Triphendiol Demonstrate Anti-proliferative Activity in Pancreatic Cancer

A rapid and aggressive spread into surrounding tissue, resistance to standard chemotherapy and a tendency to recur make pancreatic cancer one of the most challenging diseases to treat. The disease is also difficult to diagnose in its early stage, and patients usually present with incurable disease. It has a high mortality rate, and so far no therapy has been shown to significantly impact survival. Pancreatic cancer is considered an orphan cancer, because of its relatively… Continue

Added by Peter Hofland, PhD on June 27, 2011 at 6:30am — No Comments

REO 017 Meets Primary Endpoint for First Part of U.S. Phase II Pancreatic Cancer Clinical Trial

Preliminary results from a U.S. Phase II clinical trial with intravenous administration of Reolysin® (Oncolytics Biotech Inc), a proprietary formulation of the human reovirus (respiratory enteric orphan virus), in combination with gemcitabine (Gemzar® Eli Lilly and Company) in patients with advanced pancreatic cancer show that the trial meets primary endpoint for first… Continue

Added by Peter Hofland, PhD on February 14, 2011 at 4:30pm — No Comments

Erlotinib Nearly Triples Progression-free Survival as First-line Therapy in Advanced Lung Cancer

For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib (Tarceva®, OSI Pharmaceuticals, Inc., and Genentech, Inc.) nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first… Continue

Added by Peter Hofland, PhD on October 9, 2010 at 10:30am — No Comments

ASCO 2010: Drug Combination Increases Survival in Advanced Lung Cancer in the Elderly

A Phase III randomized, multicenter trial shows that a combination of two commonly used chemotherapy drugs, paclitaxel (Taxol®) and carboplatin, significantly increases overall survival and progression-free survival (PFS) in patients age 70 or older with advanced non-small cell lung cancer (NSCLC) compared to standard single-agent therapy.

Incidence of advanced NSCLC in the elderly is increasing. But, notes lead author Elisabeth Quoix, MD, professor of… Continue

Added by Peter Hofland, PhD on June 6, 2010 at 11:30am — No Comments